Steatohepatitis-liver cancer model animal
AssigneeStelic Institute of Regenerative Medicine, Stelic Institute & Co.
InventorsHiroyuki Yoneyama, Masato Fujii
Life of this patent
Estimating the term…
Abstract
Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.
Claims11
A non-human animal model, which is produced by:
- (a) administering to a non-human mammal of one to five days old an N-acetyl-β-D-glucosaminidase inhibitor in an amount sufficient to induce organ inflammation wherein the inhibitor is selected from the group consisting of streptozotocin and Pugnac;
- (b) rearing the mammal with a high-fat diet over a period of time sufficient to induce liver cirrhosis;
- and
- (c) further rearing the mammal with a high-fat diet over a period of time sufficient to induce liver cancer caused by cirrhosis, developed such that it displaces normal liver cells of the mammal.
A non-human animal model, which is produced by:
- (a) administering to a non-human mammal of one to five days old an N-acetyl-β-D-glucosaminidase (O-GlcNAcase) inhibitor in an amount sufficient to induce organ inflammation wherein the inhibitor is a nucleic acid sequence suppressing expression of an O-GlcNAcase gene;
- (b) rearing the mammal-with a high-fat diet over a period of time sufficient to induce liver cirrhosis;
- and
- (c) further rearing the mammal with a high-fat diet over a period of time sufficient to induce liver cancer caused by cirrhosis, developed such that it displaces normal liver cells of the mammal.
Dependencies are inferred from the claim text.